BIOTECH SCANNER
@BIOTECHSCANNER
Followers
8K
Following
16K
Media
2K
Statuses
13K
18 years pharma exp in Diabetes, Obesity, Cardio, Renal, Metabolic, Respiratory diseases. Picking biotechs + solid pipelines+buyout potential with in-depth DD.
Joined June 2021
How to identify great biotech companies. Also my track record below. 1. Undervalued (low market cap vs assets and market potential) 2. Solid management (biotech experience, CEO track record and reputation, not too many turnovers) 3. Great pipeline versus what’s currently
37
12
112
Happy Thanksgiving!!!🍁🦃 I am very thankful for my family and good health. I am grateful for the 🐉 community!
4
0
40
I am praying for the families of the two National Guardsmen who have died due to being shot by an Afghan national. I have worked with so many doctors who are Muslims. They are some of the nicest people I have ever met. Unfortunately we have these extremists who ruined it for
4
1
29
$IOVA - Please correct the typo @IovanceBio and @TargetedOnc The OS rate should be 5 - year instead of “5-month.” C’mon now! “In terms of survival, the median overall survival (OS) for the overall population was 13.9 months (95% CI, 10.6–17.8), and the 5-month OS rate was
🔬 Lifileucel shows sustained efficacy and safety in advanced #melanoma, highlighting its potential as a key treatment for ICI-resistant cases.
3
1
32
$AQST - Sad to see Dr. Carl Kraus at another company but definitely wishing him the best!
3
0
14
$AQST $IOVA - This is a big surprise to me. I thought Dr. Richard Pazdur, the new director of the Center for Drug Evaluation and Research (CDER) would be on board with the National Priority Voucher program. Apparently not!
5
0
19
$IOVA - This is an important read. As I have mentioned, the head of CBER, Dr. Vinay Prasad is no friend to Pharma. That’s good and bad. I agree with many of his views but I also think he is on a more extreme end of anti-pharma. Not a coincidence that we have seen a flurry of CRLs
Key points from Prasad on FDA research •At FDA, published research represents the agency, not an individual. •Because FDA research uses taxpayer money and influences public trust, it must: •Serve the regulatory mission. •Be accurate, defensible, and high-quality. •Avoid the
3
1
17
$AQST - I will release DD on AQST the first week of December. I apologize for the delay. I am going to wait for the craziness to be less hopefully in December.
2
0
18
$AQST - Before the weekend is over, I just want you to know that this company’s future is incredibly bright. We are literally about months away from changing the world and saving so many lives. There’s nothing like losing a loved one to anaphylaxis. Many times it happens right in
3
0
28
For some reason, today’s green feels like a bull trap. There’s so much uncertainties still yet one company’s earnings caused the sudden surge. But any day that shorts are liquidated is a great day! 😀
2
0
29
Hang in there fam. It’s going to be a rough week. Very volatile right now. I’m working on new $IOVA and $AQST DD packages. I probably will have them done in the first week of December. This is a quiet period for both of these tickers. They will be range bound for a while. 2026
5
2
54
$RKLB - Market cap $24B. SpaceX valuation at approximately $350B. Yes, we don’t have enough shares. Rocket Lab is a full vertically integrated space logistics company. Yes, the valuation gap between these companies will narrow tremendously in the near future.
1
0
10
$IOVA $RKLB - Keep collecting future treasures with these. We don’t have enough shares 🤑
3
0
19
Have a blessed weekend friends! Enjoy your time with your friends and family! See you back on Monday!
2
0
16
$RKLB - Warning ‼️ Do not watch this video if you don’t have dry powder!!! https://t.co/B5FxeO8CXn
1
0
5